Vision Gains Reported in Dry AMD Patients Using the Nova Oculus III
Canada – April 2024 – Nova Oculus CEO Steven Hite recently visited the clinic of Dr. Michael Nelson in Canada to observe the use of the Nova Oculus III microcurrent therapy device in treating patients with dry Age-related Macular Degeneration (AMD).
Dr. Nelson expressed his enthusiasm for the new technology, stating, “I am excited to share with you about a new emerging treatment that can benefit people with dry macular degeneration. And it’s super exciting because it actually can improve their vision.”
He elaborated on his experience with the Nova Oculus III, saying, “I’ve had the opportunity to try out the Nova Oculus III microcurrent technology to treat macular degeneration to see what’s experienced in the actual treatment using microcurrent technology. In my experience, I found this treatment was easy to do, both from the doctor’s point of view and also for the patients setting it up and performing it and participating in the treatment.”
Dr. Nelson reported significant improvements in his patients’ visual acuity after just a few treatments. “The patients that I saw only had about two or three treatments, and what was great to see was that even in those short few treatments, they all had a little bit of improvement by about one, one and a half lines of their visual acuity, which is pretty incredible in a short period of time,” he shared.
ABOUT DR. NELSON
Dr. Nelson is currently the Geographic Representative for North America for the World Council of Optometry. He has served as the president of the Manitoba Association of Optometrists from 2000-2003 and is currently (2021-2022) the Past-President of the Canadian Association of Optometrists. He is also a board member of Eye Recommend, a co-op of independent Canadian optometrist business owners. Dr. Nelson also enjoys educating the public on all topics related to the eye on his YouTube channel “Good Optometry Morning” with an episode regarding AMD and this microcurrent therapy posted on our website.